No abstract

The prognosis of allergic rhinitis was studied in 154 children aged 3-17 years at diagnosis by means of a detailed questionnaire administered 8-11 years later. The symptoms had completely disappeared in only 15 (10%) patients. The conjunctival symptoms, however, had disappeared or were controlled successfully by topical drug therapy in almost all, and 77 (50%) were managing without medication for allergic rhinitis. Twenty-five (23%) of the 110 children with seasonal allergic rhinitis had a perennial disease at follow-up, in contrast to seven (16%) of 44 with perennial allergic rhinitis originally who had only seasonal symptoms at follow-up. Asthma or wheezing had developed in 29 cases (19%) and was more common (p less than 0.01) among those with perennial allergic rhinitis (15 of 44) than among those with seasonal allergic rhinitis (14 of 110). No significant association was found between age at onset of symptoms, family history of atopic disease or type of treatment for allergic rhinitis and allergic rhinitis still present at follow-up or development of asthma during the observation period.

Forty children treated in our hospital for generalized infantile eczema were re-examined at 11-13 years of age. In 7 (18%) children the eczema had disappeared and in 26 (65%) it had become less severe. Unrelated to dermatological status or gender, allergic rhinitis was diagnosed in 31 (78%) and asthma in 21 (53%) children. Only 8 children continued without either of these two conditions. All 32 children with allergic rhinitis and/or asthma showed at least one positive skin test reaction in a test panel of 11 common inhalant and food allergens compared with only 4 of 8 children without either allergic rhinitis or asthma (p < 0.001). Our results showed an improvement of dermatological status in most children with generalized infantile eczema but there was a high risk of a concomitant respiratory allergy and development of allergic rhinitis or asthma.

The value of spirometry, the bronchodilator test and 2 weeks' symptom scoring for the assessment of the severity of childhood asthma was studied in a series of 65 consecutively referred school-aged asthmatic children, with the diurnal peak expiratory flow (PEF) variability in home recordings serving as a golden standard. The amplitude of the peak expiratory flow rate (PEFR) variation could be best predicted by the baseline forced expiratory volume in 1 s (FEV1) and the past history of the symptom rate, the correlation with FEV1 being -0.48, p < 0.001. Although the baseline forced expiratory flow between 25 and 75% of the forced vital capacity (FEF25-75%) and the responses of FEV1 and FEF25-75% to salbutamol also showed significant correlations with the diurnal PEFR variability (r = -0.43, r = 0.47 and 0.41, p < 0.001, respectively), these variants did not improve the regression model. The baseline FEV1. FEF25-75% and PEFR and their responses to salbutamol also had a slight but statistically significant correlation with the methacholine threshold, but the symptom score on the diary card did not show comparable correlations with either the diurnal PEFR variability or the methacholine threshold (r = 0.09, NS, and r = 0.05, NS, respectively). These results indicate that both baseline lung function and the response to the bronchodilator test correlate with the severity of childhood asthma more appropriately than does the symptom score on a diary card. Since many of these correlations were rather weak, however, the assessment of the severity of childhood asthma cannot be reliably based solely on spirometry in all patients.

Aim: The aim of the present study was to investigate the characteristics of hospital admissions in two child populations receiving different types of drugs as their regular medication for steady‐state asthma. Methods: Annual data on children aged under 16 y treated for asthma, including consumption of regular medication for asthma, numbers of hospital periods, lengths of hospitalizations and annual proportions of readmissions, were collected using patient‐specific medical records from 1995 to 1999. In the Kuopio province, on average, 35.6–36.7/1000 children were on maintenance for asthma, of which 23% were receiving cromones, 51% were taking inhaled steroids and 26% were treated with cromones plus intermittent steroids. In the Oulu province, the respective prevalence was 32.7–34.9/1000, and the respective proportions were 5%, 93% and 2%. Results: Total and first admissions, as well as hospital days were clearly less in the Oulu province. In the children aged ≥6 y, the average annual total admissions were 0.3/1000 (Oulu) vs 1.2/1000 (Kuopio) (p < 0.001). Similarly, the first admissions were 0.2/1000 vs 1.0/1000 (p < 0.001), proportions of readmissions 6.3% vs 19.3% (p < 0.05), and numbers of hospital days 0.7/1000 vs 3.8/1000 (p < 0.001). The differences were in the same direction, though less prominent, also among children 2–5 y of age. Conclusion: Our results suggest that inhaled steroids are better than cromones in preventing admissions for asthma when two provinces with different practices for maintenance medication of steady‐state asthma were compared.